The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Adzynma Takeda Pharmaceuticals Australia Pty Ltd
Product name
Adzynma
Accepted date
Jan-2025
Active ingredients
apadamtase alfa
Proposed indication
ADZYNMA is a treatment that replaces a missing enzyme, ADAMTS13. It's used to treat people who have a condition called congenital thrombotic thrombocytopenic purpura. People with this condition have low levels of ADAMTS13 in their bodies. ADZYNMA can be used by people of all ages.
Application type
A (new medicine)
Publication date
Jan-2025
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.